Scott has served as Chief Medical Officer of Altimmune, developing therapeutics in obesity, metabolic disease and liver disease since 2019. He has nearly 25 years of experience in drug development. He co-founded Lyric Pharmaceuticals in 2015 and played a role in approval and commercialization of drugs at various public and private companies. He served as a consultant to the Bill and Melinda Gates Foundation in pediatric diarrheal disease and collaborated with FDA on forums in drug development. Scott has an M.D. from Harvard Medical School. He completed medical residencies at John Hopkins Hospital and the University of Pennsylvania and a Gastroenterology and Hepatology Fellowship at Yale University School of Medicine. He holds a seat on the faculty of Georgetown University School of Medicine, where he teaches a graduate course in drug development.